Bahl & Gaynor Inc. Sells 90,516 Shares of Amgen Inc. $AMGN

Bahl & Gaynor Inc. reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 31.3% during the third quarter, Holdings Channel reports. The institutional investor owned 198,402 shares of the medical research company’s stock after selling 90,516 shares during the period. Bahl & Gaynor Inc.’s holdings in Amgen were worth $55,989,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. New Age Alpha Advisors LLC lifted its holdings in Amgen by 3.0% during the third quarter. New Age Alpha Advisors LLC now owns 41,651 shares of the medical research company’s stock valued at $11,754,000 after purchasing an additional 1,211 shares in the last quarter. Holderness Investments Co. increased its stake in shares of Amgen by 2.2% in the third quarter. Holderness Investments Co. now owns 7,786 shares of the medical research company’s stock worth $2,197,000 after purchasing an additional 169 shares in the last quarter. Patrick M Sweeney & Associates Inc. raised its position in shares of Amgen by 6.4% during the 3rd quarter. Patrick M Sweeney & Associates Inc. now owns 1,037 shares of the medical research company’s stock valued at $293,000 after purchasing an additional 62 shares during the period. Strategies Wealth Advisors LLC purchased a new position in shares of Amgen during the 3rd quarter valued at $278,000. Finally, 49 Wealth Management LLC boosted its holdings in Amgen by 4.6% in the 3rd quarter. 49 Wealth Management LLC now owns 1,151 shares of the medical research company’s stock worth $325,000 after buying an additional 51 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

AMGN has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft raised their price target on Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a report on Thursday, February 5th. TD Cowen reissued a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Wells Fargo & Company boosted their price target on Amgen from $325.00 to $375.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. Freedom Capital lowered shares of Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 12th. Finally, Cantor Fitzgerald boosted their target price on shares of Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $351.76.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported a new evolocumab bioavailability study that refines dosing/PK assessment for its PCSK9 cholesterol franchise, signaling management’s continued investment in a long‑lived cardiovascular product line and potential lifecycle optimization. Amgen Fine-Tunes Evolocumab
• Positive Sentiment: Amgen advanced maridebart (cafraglutide) toward a Phase 2b obesity and liver‑fat trial — news that expands the company’s obesity pipeline and supports upside potential beyond core biologics. Pipeline progress tends to lift pharma multiples. Amgen Advances Maridebart
• Positive Sentiment: Coverage and momentum narratives are supportive — Zacks highlights AMGN as a top long‑term momentum stock, which can attract trend‑driven and fund flows. Why Amgen is a Top Momentum Stock
• Positive Sentiment: Market headlines note AMGN reaching an all‑time high and outperforming the Dow recently — reinforcement for bullish sentiment and potential technical buying. Amgen stock hits all-time high Is Amgen Stock Outperforming the Dow?
• Neutral Sentiment: Biotech sector activity: a large biotech IPO (Generate Biomedicines) indicates healthy capital markets for life sciences, which can be a neutral tailwind for large biotech names but doesn’t directly change Amgen’s fundamentals. Generate caps a strong month for biotech IPOs
• Neutral Sentiment: Minor portfolio rebalancing: a small sale by Bradley Foster & Sargent reduced a modest position in AMGN — not material to shares outstanding or sentiment. Bradley Foster & Sargent sells AMGN
• Negative Sentiment: Policy risk: a proposed U.S. bill to tighten rules on corporate inversions mentions AMGN among companies potentially affected by changes to international tax treatment — could raise longer‑term tax/structural uncertainty if enacted. Impact is uncertain and likely small near term. Stop Corporate Inversions Act of 2026
• Neutral Sentiment: Reported short‑interest data in feeds looks inconsistent (zeros/NaN) and should be treated with caution; no clear signal from short interest trends. (data sources above).

Amgen Stock Up 2.3%

NASDAQ AMGN opened at $388.16 on Monday. The stock has a 50 day moving average price of $348.89 and a 200-day moving average price of $319.93. Amgen Inc. has a one year low of $261.43 and a one year high of $390.14. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The company has a market capitalization of $209.25 billion, a P/E ratio of 27.28, a P/E/G ratio of 3.85 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter in the prior year, the firm earned $5.31 earnings per share. Amgen’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be given a $2.52 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a yield of 2.6%. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.